An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease

被引:62
|
作者
Wilsey, Barth [1 ,2 ]
Marcotte, Thomas D. [3 ]
Deutsch, Reena [3 ]
Zhao, Holly [1 ,2 ]
Prasad, Hannah [1 ,2 ]
Phan, Amy [1 ,2 ]
机构
[1] Sacramento VA Med Ctr, VA Northern Calif Hlth Care Syst, Mather, CA USA
[2] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Lawrence J Ellison Ambulatory Care Ctr, Sacramento, CA USA
[3] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
基金
美国国家卫生研究院;
关键词
Neuropathic pain; analgesia; cannabis; clinical trial; neuropsychological testing; SERIAL-ADDITION TASK; MULTIPLE-SCLEROSIS; CLINICAL IMPORTANCE; SMOKED MARIJUANA; DOUBLE-BLIND; SUICIDAL BEHAVIORS; DRONABINOL; CROSSOVER; SYMPTOMS; EFFICACY;
D O I
10.1016/j.jpain.2016.05.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Using 8-hour human laboratory experiments, we evaluated the analgesic efficacy of vaporized cannabis in patients with neuropathic pain related to injury or disease of the spinal cord, most of whom were experiencing pain despite traditional treatment. After obtaining baseline data, 42 participants underwent a standardized procedure for inhaling 4 puffs of vaporized cannabis containing either placebo, 2.9%, or 6.7% delta 9-THC on 3 separate occasions. A second dosing occurred 3 hours later; participants chose to inhale 4 to 8 puffs. This flexible dosing was used to attempt to reduce the placebo effect. Using an 11-point numerical pain intensity rating scale as the primary outcome, a mixed effects linear regression model showed a significant analgesic response for vaporized cannabis. When subjective and psychoactive side effects (eg, good drug effect, feeling high, etc) were added as covariates to the model, the reduction in pain intensity remained significant above and beyond any effect of these measures (all P <.0004). Psychoactive and subjective effects were dose-dependent. Measurement of neuropsychological performance proved challenging because of various disabilities in the population studied. Because the 2 active doses did not significantly differ from each other in terms of analgesic potency, the lower dose appears to offer the best risk-benefit ratio in patients with neuropathic pain associated with injury or disease, of the spinal cord. Perspective: A crossover, randomized, placebo-controlled human laboratory experiment involving administration of vaporized cannabis was performed in patients with neuropathic pain related to spinal cord injury and disease. This study supports consideration of future research that would include longer duration studies over weeks to months to evaluate the efficacy of medicinal cannabis in patients with central neuropathic pain. (C) 2016 by the American Pain Society
引用
收藏
页码:982 / 1000
页数:19
相关论文
共 50 条
  • [1] Diagnosis and pharmacological treatment of neuropathic pain in spinal cord injury subjects: from laboratory to clinical trial
    Xifro, Xavier
    Puig, Teresa
    Boadas-Vaello, Pere
    MEDICINA CLINICA, 2013, 140 (04): : 175 - 181
  • [2] Progress in treatment of pathological neuropathic pain after spinal cord injury
    Li, Jian
    Kang, Wenqing
    Wang, Xi
    Pan, Fang
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [3] A preliminary study evaluating self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in people with spinal cord injury
    Kinnunen, Kristiina
    Robayo, Linda E.
    Cherup, Nicholas P.
    Frank, Scott I.
    Widerstrom-Noga, Eva
    FRONTIERS IN PAIN RESEARCH, 2023, 4
  • [4] Neuropathic pain following spinal cord injury pain: mechanisms and treatment
    Finnerupa, Nanna Brix
    Baastrupa, Cathrine
    Jensena, Troels Staehelin
    SCANDINAVIAN JOURNAL OF PAIN, 2009, 1 : S3 - S11
  • [5] Pharmacologic Treatment of Neuropathic Pain Following Spinal Cord Injury
    DeFrates, Sean
    Cook, Aaron M.
    ORTHOPEDICS, 2011, 34 (03) : 203 - 207
  • [6] Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
    Allison, David J.
    Thomas, Aysha
    Beaudry, Kayleigh
    Ditor, David S.
    JOURNAL OF NEUROINFLAMMATION, 2016, 13
  • [7] Neuropathic Pain Induced by Spinal Cord Injury from the Glia Perspective and Its Treatment
    Ye, Ying
    Su, Xinjin
    Tang, Jun
    Zhu, Chao
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2024, 44 (01)
  • [8] Future Treatment of Neuropathic Pain in Spinal Cord Injury: The Challenges of Nanomedicine, Supplements or Opportunities?
    Forte, Giuseppe
    Giuffrida, Valentina
    Scuderi, Angelica
    Pazzaglia, Mariella
    BIOMEDICINES, 2022, 10 (06)
  • [9] Neuropathic Pain Following Spinal Cord Injury: Mechanism, Assessment and Treatment
    Civelek, Gul Mete
    Afsar, Sevgi Ikbali
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 : 909 - 912
  • [10] Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury
    Levendoglu, F
    Ögün, CÖ
    Özerbil, Ö
    Ögün, TC
    Ugurlu, H
    SPINE, 2004, 29 (07) : 743 - 751